British Airways Pensions Investment Management Ltd Purchases New Holdings in Bioverativ Inc (BIVV)
British Airways Pensions Investment Management Ltd purchased a new position in shares of Bioverativ Inc (NASDAQ:BIVV) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 264,529 shares of the biotechnology company’s stock, valued at approximately $15,093,000. British Airways Pensions Investment Management Ltd owned approximately 0.24% of Bioverativ as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the business. Woodford Investment Management Ltd bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $85,455,000. Old Mutual Global Investors UK Ltd. bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $96,827,000. Bank of New York Mellon Corp bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $71,032,000. Jennison Associates LLC bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $56,420,000. Finally, Frontier Capital Management Co. LLC bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $54,653,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.
Shares of Bioverativ Inc (BIVV) traded up $0.79 during trading hours on Thursday, hitting $55.18. The stock had a trading volume of 1,156,600 shares, compared to its average volume of 1,615,656. Bioverativ Inc has a one year low of $40.00 and a one year high of $64.41.
Bioverativ (NASDAQ:BIVV) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. Bioverativ’s revenue was up 27.2% compared to the same quarter last year. research analysts predict that Bioverativ Inc will post 2.45 EPS for the current fiscal year.
A number of research firms have issued reports on BIVV. Zacks Investment Research cut Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 1st. Piper Jaffray Companies restated an “overweight” rating and set a $71.00 price target on shares of Bioverativ in a report on Monday, October 23rd. Morgan Stanley restated an “underweight” rating and set a $47.00 price target (up from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Argus upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a report on Wednesday, September 20th. Finally, Royal Bank Of Canada began coverage on Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target on the stock. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Bioverativ presently has an average rating of “Hold” and an average price target of $61.73.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Stock Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related stocks with our FREE daily email newsletter.